Project Grant R01DA061769
Award Date 9/1/25
Completion Date 5/31/28
Dollars Obligated $637K
Funding Federal Agency
Awarding Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Washington, USA
Similar Awards
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $495,950 to The Washington University in Missouri to investigate the mechanisms involving mu opioid receptor (MOR) signaling within the nucleus of the solitary tract (NTS) that contribute to fentanyl-induced cardiorespiratory depression. The 3-year project, commencing on Sept 1, 2025, aims to employ various techniques such as chemogenetics, optogenetics, and...
- This Project Grant award from the National Institutes of Health (NIH) under the Trans-NIH Research Support program (CFDA 93.310) provides $671,732.00 to The Washington University to conduct research on the mechanisms underlying fentanyl-induced cardiorespiratory depression. The project aims to evaluate peripherally-acting mu opioid receptor antagonists as a potential treatment strategy to reverse opioid-induced respiratory depression without precipitating withdrawal or aversion, which is a...
- This federal Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) aims to develop a wireless bioelectronic system for high-performance fentanyl monitoring in the brains of freely moving small animal models. The $358,371 award, effective from October 1, 2025 to September 30, 2028, will support three key objectives: Isolating, characterizing, and engineering aptamers (targeting molecules) for the primary opioid fentanyl associated with opioid use...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $139,927 to the University of Washington to study the impact of chronic, voluntary fentanyl intake on gene expression and neural activity patterns in the brain. The key objectives are to: 1) Conduct single-cell RNA sequencing analysis of the nucleus accumbens to assess changes in gene expression following chronic fentanyl self-administration and...
- The University of Washington was awarded a $2.2 million project grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research from January 2021 through January 2025 to rapidly test a novel therapeutic strategy for COVID-19 using human organoids and blood vessel structures. Through this funding, the University of Washington will investigate medical solutions for COVID-19 using...
- The University of Washington received a $777,497 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) to conduct a hybrid implementation-effectiveness study of a pharmacist-led collaborative care model to improve access to hepatitis C treatment for people who use drugs with housing insecurity. The 5-year project aims to evaluate the reach, adoption, effectiveness, and maintenance of the "Pharmacist, Physician, Patient...
- This $2,267,819 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Abuse and Addiction Research Programs) will fund research by the University of Washington to characterize extracellular vesicle (EV) profiles in healthy pregnancies and those complicated by opioid use disorder. The goal is to identify biomarkers in placental EVs and fetal brain/central nervous system EVs that could predict an infant's risk of developing neonatal opioid withdrawal syndrome (NOWS) and...
- This Cooperative Agreement, awarded by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279), provides $2,664,000.00 in funding to The Washington University to develop negative allosteric modulators (NAMs) of the mu opioid receptor as potential treatments for opioid overdose and opioid use disorder. The key products and services to be delivered through this 2-year award, which runs from September 1, 2025 to August 31, 2027, include...
- This $478,962 federal Project Grant award from the National Science Foundation (NSF) Engineering program (CFDA 47.041) to Clemson University aims to mitigate the harm caused by illicit opioid use, particularly fentanyl, through a convergent research approach. The project will investigate methods to disrupt the supply chain of illicit opioids and shift user pathways towards recovery, while optimizing the allocation of resources between demand- and supply-side interventions. Key research...
- This Project Grant from the National Institutes of Health National Institute on Drug Abuse, under the Drug Abuse and Addiction Research Programs (CFDA 93.279), provides $889,713 to The Ohio State University from April 2021 through March 2023. The funding supports research to develop dual-cavity baskets assembled into nanoparticles as nano-antidotes for overdose with fentanyl and its derivatives. Specifically, the awardee will functionalize dual-cavity baskets with biocompatible groups to trap...